The OTEZLA® international website

This site is intended for healthcare professionals outside the U.S.

Country Sites U.S. Residents

Plaque  Psoriasis

Plaque  Psoriasis

Clinical Efficacy

Clinical Efficacy

Safety

Safety

Dosing

Dosing

Mechanism of Action

Mechanism of Action

Testimonials

Testimonials

About Psoriasis

About Psoriasis

Resources

Resources

Psoriatic  Arthritis

Psoriatic  Arthritis

Clinical Efficacy

Clinical Efficacy

Safety

Safety

Dosing

Dosing

Mechanism of Action

Mechanism of Action

About Psoriatic Arthritis

About Psoriatic Arthritis

Treatment Recommendations

Treatment Recommendations

Resources

Resources

OTEZLA DELIVERS BROAD AND SUSTAINED EFFICACY1-5

Psoriasis is a systemic disease characterized by multiple manifestations, including some that are difficult to treat2-5

Choose a domain to see the efficacy of OTEZLA in psoriasis

Human silhouette with hyperlinked hot spots that link to pages with information about the efficacy of OTEZLA® (apremilast) in treating the manifestations of psoriasis: scalp psoriasis, skin plaques, pruritus, palmoplantar psoriasis, and nail psoriasis

References:

  1. Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73:37-49.
  2. Sobell JM, Foley P, Toth D, et al. Effects of apremilast on pruritus and skin discomfort/pain correlate with improvements in quality of life in patients with moderate to severe plaque psoriasis. Acta Derm Venereol. 2016;96(4):514-520.
  3. Crowley J, Gooderham M, Wasel N, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: results of two phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). Presented at: the 73rd Annual Meeting of the American Academy of Dermatology; March 20-24, 2015; San Francisco, CA.
  4. Rich P, Gooderham M, Bachelez H, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: results of two phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). J Am Acad Dermatol. 2015;74(1):134-142.
  5. Bissonnette R, Pariser DM, Wasel NR, et al. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis. J Am Acad Dermatol. 2016;75(1):99-105.
You are leaving the OTEZLA® (apremilast) website
Do you wish to leave this site?
OTEZLA International Websites
OTEZLA is approved in 54 countries*

  • United States

  • Canada

  • Australia

  • Israel

  • Switzerland

  • New Zealand

  • Austria

  • Belgium

  • Bulgaria

  • Croatia

  • Republic of Cyprus

  • Czech Republic

  • Denmark

  • Estonia

  • Finland

  • France

  • Germany

  • Greece

  • Hungary

  • Ireland

  • Italy

  • Latvia

  • Lithuania

  • Luxembourg

  • Malta

  • Netherlands

  • Poland

  • Portugal

  • Romania

  • Slovakia

  • Slovenia

  • Singapore

  • Spain

  • Sweden

  • United Kingdom

  • Norway

  • Iceland

  • Liechtenstein

  • Russia

  • Japan

  • Hong Kong

  • Kuwait

  • Taiwan

  • UAE

  • South Korea

  • Thailand

  • Lebanon

  • Qatar

  • Argentina

  • Mexico

  • Brazil

  • Malaysia

  • Oman

  • Saudi Arabia

On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).

Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.

For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.